Sanofi-Aventis Will Enter U.S. OTC Market By Paying $1.9 Billion For Chattem
This article was originally published in The Pink Sheet Daily
Executive Summary
The deal, which is Sanofi's latest attempt to diversity in the face of a looming patent cliff, provides a platform for Rx-to-OTC switches.
You may also be interested in...
Sanofi Looks To Lead In Consumer Following Trade With Boehringer Ingelheim
Sanofi will trade Merial animal health for most of Boehringer Ingelheim’s OTC drug and supplement business as both drug makers look to build critical mass in key diversified areas. Consumer healthcare is poised to become Sanofi’s second top-selling franchise after diabetes.
Sanofi Looks To Lead In Consumer Following Trade With Boehringer Ingelheim
Sanofi will trade Merial animal health for most of Boehringer Ingelheim’s OTC drug and supplement business as both drug makers look to build critical mass in key diversified areas. Consumer healthcare is poised to become Sanofi’s second top-selling franchise after diabetes.
Pfizer: Established Products And Consumer Health In; Animal Health And Nutrition Out
Pfizer takes a middle-of-the-road approach to breaking out non-core businesses, announcing plans to explore alternatives for Animal Health and Nutrition.